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Aim: Over 7 million traumatic brain injuries (TBI) are reported each year in the United States.
However, treatments and neuroprotection following TBI are limited because secondary injury
cascades are poorly understood. Lipopolysaccharide (LPS) administration before controlled
cortical impact can contribute to neuroprotection. However, the underlying mechanisms and
whether LPS preconditioning confers neuroprotection against closed-head injuries remains
unclear. Methods: The authors hypothesized that preconditioning with a low dose of LPS
(0.2 mg/kg) would regulate glial reactivity and protect against diffuse axonal injury induced
by weight drop. LPS was administered 7 days prior to TBI. LPS administration reduced
locomotion, which recovered completely by time of injury. Results: LPS preconditioning
significantly reduced the post-injury gliosis response near the corpus callosum, possibly by
downregulating the oncostatin M receptor. These novel findings demonstrate a protective
role of LPS preconditioning against diffuse axonal injury. LPS preconditioning successfully
prevented neurodegeneration near the corpus callosum, as measured by fluorojade B.
Conclusion: Further work is required to elucidate whether LPS preconditioning confers
long-term protection against behavioral deficits and to elucidate the biochemical mechanisms
responsible for LPS-induced neuroprotective effects.

This is an open access article distributed under the terms of the Creative Commons AttributionNonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work
non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
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INTRODUCTION

METHODS

Endotoxin preconditioning with lipopolysaccharide
(LPS) was previously shown to be neuroprotective in
models of ischemic stroke and traumatic brain injury
(TBI).[1] The neuroprotective mechanisms of LPS
remain unclear, particularly with regards to vascularmediated effects. Prior studies have studies this
using contusion-based models of neurotrauma. The
contusion model irreversibly injures a focal brain
region, creating a gross structural void associated
with significant vascular injury.[2] The mechanisms
of LPS preconditioning are poorly understood
and have not been studied in a model of diffuse
axonal injury. There is emerging evidence that proinflammatory regulation is neuroprotective in models
of neural injury,[3] particularly the regulation of proinflammatory cytokines and microglial phenotype
changes. Microglia is pleiotropic and transition
between continuum states. These states are termed
M1 or M2 depending on the inciting events.[4]
Microglia may have protective and destructive roles,
depending on the transition state.[5] The ratio of
microglial states can predict the subacute outcome
following injury. M1 microglia are pro-inflammatory
and can cause long-term deficits.[6] Although LPS
has been shown to influence astrocyte phenotypes,
it is not clear whether LPS preconditioning
modulates microglial phenotypes following diffuse
axonal injury.[7]

Animals

In this study, we investigated the neuroprotective
effect of LPS preconditioning in a closed-head
model of diffuse axonal injury for the first time. This
model of TBI has increased clinical relevance due to
axonal shearing seen with diffuse neurotrauma.[8] We
hypothesized that LPS preconditioning would reduce
inflammation and neurodegeneration following
diffuse axonal injury. In addition, we predicted that
LPS preconditioning would regulate the oncostatin
M receptor (OSMR) in astrocytes and activate the
M1 microglia phenotype after TBI. TBI promotes
pro-inflammatory cascades and increases the
expression of glial fibrillary acidic protein (GFAP);[2,9]
however, a link between astrocyte regulation and
the microglia phenotype after TBI has not been
investigated. In this study, we explored the effect
of LPS preconditioning on astrocytes and microglia
and addressed the relationship between cytokine
receptor expression, astrocyte reactivity, and
microglial phenotype. Improving our understanding
of the protective effects of LPS preconditioning may
accelerate the identification of novel therapeutic
targets that reduce damage after TBI in individuals
at risk of concussion.

All procedures involving live animals were approved
by the Institutional Animal Care and Use Committee
of West Virginia University and were performed
according to the principles of the Guide for the
Care and Use of Laboratory Animals, published
by the Institute of Laboratory Resources, National
Research Council (National Institutes of Health
publication 85-23-2985). Thirty-two male Sprague
Dawley rats (Hilltop) at 3-4 months of age were
used in this study. Animals were given standard rat
chow and water ad libitum.

LPS preconditioning

Rats were pretreated with a single intraperitoneal
injection of either 0.2 mg/kg LPS (Sigma-Aldrich) or
0.9% saline (equal volume) 7 days prior to TBI.

Locomotor behavior

After LPS injection, the development of sickness
behavior was monitored using activity chambers
as described by Godbout et al.[10] Locomotor
activity was assessed using an automated activity
monitoring system (San Diego Instruments, San
Diego, CA) that recorded beam breaks in the x, y,
and z planes. Animals were acclimated to the room
for 1 h prior to testing. Testing chambers consisted of
square Plexiglass housing and 16 × 16 photobeam
arrays to detect lateral movements. An 8 × 8 array,
located above the 16 × 16 array, detected rearingassociated movements. Activity was quantified over
30 min and the sum of fine, ambulatory, and rearing
beam breaks was calculated to give the total number
of beam breaks. These recordings were completed
at 2, 4, 24, and 48 h post-injection.

TBI induction

Animals were divided into four groups: sham surgery
(n = 8), sham surgery with LPS pretreatment (n
= 8), impact-acceleration injury following saline
injection (n = 8), and impact-acceleration injury with
LPS pretreatment (n = 8). Anesthesia was induced
and maintained using isoflurane (4% induction, 2%
maintenance). Body temperature was controlled
with a homeothermic heating blanket equipped
with a rectal probe. Rats received an impactacceleration injury as described previously.[11-13]
Briefly, a 10-mm diameter and 3-mm thick stainless
steel disk was affixed to the skull with cyanoacrylate
between bregma and lambda. The animal was
placed in a prone position on a foam bed with a
metal disk directly beneath a 2-m tall Plexiglass tube.
A 450-g weight was dropped from the top of the
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tube, striking the metal disk. The disk was then
removed while the rat was under anesthesia, the
skull inspected, and the wound sutured. The animal
was then returned to its cage, which was placed on
a heating pad. Recovery from injury and anesthesia
were monitored. No mortality was observed with
the current injury parameters, and no gross lesions
were apparent at the time of sacrifice indicating mild
diffuse axonal injury.

Tissue preparation

Seven days after TBI, animals were anesthetized
and perfused transcardially with physiological saline.
Brains were removed and sectioned for histological
analysis. The frontal cortex was selected for
histological analysis. Tissue sections were placed
in 4% paraformaldehyde for a minimum of 1 week.
Following fixation, brains were processed using
a Tissue-Tek VIP 5 Automatic Tissue Processor
(Sakura Finatek, Torrence, CA). Processed tissues
were paraffin-embedded with Tissue-Tek Tec 5
embedding system (Sakura Finatek, Torrence, CA)
and sliced (6 µm) using a Leica RM2235 microtome
(Leica Microscopes, Buffalo Grove, IL). Sections
were mounted on glass slides and heat-fixed.
Immediately prior to staining, tissues were deparaffinized with xylene and alcohol washes.[14]

Fluoro-Jade B (FJB) staining

FJB staining was used to identify neural degeneration.
For FJB labelling, slides were rehydrated through a
series of alcohol and deionized (dH2O) water rinses
then incubated in 0.06% potassium permanganate
for 10 min. Then, slides were rinsed for 2 min in
dH2O water and incubated with FJB in 0.1% acetic
acid for 20 min. After staining, slides were washed
three times in dH2O.

GFAP staining

Tissues were incubated in rabbit anti-cow GFAP
antibody (Dako, Glostrup, Denmark) at a dilution of
1:500 in 4% horse serum in Dulbecco’s phosphate
buffered (DPBS) overnight. Then, tissues were
washed three times in DPBS and incubated in
biotinylated anti-rabbit IgG antibody (Vector
Laboratories, Burlingame, CA) diluted at 1:10,000
in 4% horse serum in DPBS for 4 h. Next, tissue was
treated with avidin D-horeradish peroxidase (Vector
Laboratories, Burlingame, CA) diluted at 1:1,000 in
DPBS for 1 h. Sections were then stained in DAB
chromogen solution (Vector Laboratories) for 5 min,
then tissues were rinsed three times in DPBS and
dried overnight.

M1 microglia staining

Tissues were incubated in mouse anti-rat CD68
8

antibody (AbD Serotec, Kidlington, UK) at a dilution
of 1:100 in 4% horse serum in DPBS overnight.
Sections were washed three times in DPBS
and incubated in a biotinylated anti-mouse IgG
secondary antibody (Vector Laboratories) diluted
at 1:10,000 in 4% horse serum in DPBS for 4 h.
Following secondary antibody incubation, tissues
were incubated in alkaline phosphatase (Life
Technology, Carlsbad, CA) diluted at 1:100 in Trisbovine serum albumin for 1 h. Then, tissues were
rinsed three times in DPBS and incubated in Fast
Blue BB salt (Santa Cruz Biotechnology, Santa
Cruz, CA) for 5 min. Tissues were washed in xylene,
mounted using an antifade agent, and cover slipped.
The slides were sealed with acrylic and stored in the
dark in a laboratory refrigerator.

GFAP and OSMR staining

Tissues were labelled with rabbit against anti-cow
GFAP (DAKO) antibody at a dilution of 1:500 in
5% horse serum in PBS overnight at 4 °C. Next,
sections were washed twice for 10 min each in
PBS prior to application of Alexa Fluor 488 goat
anti-rabbit IgG (Invitrogen, Grand Island, NY) at a
dilution of 1:100 in PBS for 3 h. Following secondary
antibody incubation, slides were rinsed twice for
10 min each in PBS. Then, tissue was labelled
with a goat anti-mouse OSMR antibody (LifeSpan
Biosciences, Seattle, WA) at a dilution of 1:200 in
5% horse serum in PBS overnight at 4 °C. Following
incubation, slides were rinsed twice for 10 min each
in PBS prior before applying biotinylated anti-goat
IgG (Vector Laboratories) at a dilution of 1:10,000
in 5% horse serum in PBS for 2 h. Next, slides were
rinsed twice for 10 min each in PBS and incubated
in Streptavidin Alexa Fluor 546 (Life Technology)
at a dilution of 1:100 in PBS for 1 h. Slides were
rinsed in PBS for 10 min and then coverslipped
with Vectashield Mounting Media containing DAPI
(Vector Laboratories). Finally, slides were sealed
with acrylic and stored in the dark in a laboratory
refrigerator at 4 oC. Images were acquired using
a Zeiss Axio Imager 2 microscope and quantified
using ImageJ with standard co-localization
quantification techniques and the co-localization
plugin established by Bolte et al.[15]

Histological quantification

Stereology and optical fractionation were used
to quantify histological results as previously
described.[16-18] Briefly, a region of interest
encompassing the corpus callosum was drawn at
low power using an Olympus AX70 microscope
and StereoInvestigator software. The region
encompassing the corpus callosum was chosen
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because it undergoes robust biochemical changes
following impact-acceleration TBI.[19] The software
selected random 75-µm counting frames with
a depth of 6 µm, and the object of interest was
marked by an investigator blinded to treatment. The
region of interest volume was previously identified,
and the number of cells marked by the observer was
quantified.

Statistical analysis

Data were analyzed using GraphPad Prism version
4.0. One-way ANOVA with post-hoc Tukey’s test
was used to compare histological findings across
control and various experimental groups. Repeated
measures two-way ANOVA was used to analyze
the total activity data. An overlap coefficient of
0.6 or greater indicated strong co-localization, a
coefficient between 0.4 and 0.6 indicated medium
co-localization, and a coefficient < 0.4 indicated
weak co-localization. A P value of < 0.05 was
considered statistically significant for all studies.

RESULTS
LPS induces
behavior

transient

acute

sickness

LPS injection induces systemic sickness in rodents
as evidenced by an acute reduction in activity.[10,20]
Figure 1 shows a significant reduction in total activity
after LPS administration compared with salinetreated animals based on time (F3,66 = 8.14, P <
0.001), treatment (F1,66 = 18.67, P < 0.001), and the
time treatment interaction (F3,66 = 22.92, P < 0.001)
using two-way repeated measures ANOVA. Total
activity was reduced by approximately 71% and
59% at 2 and 4 h post-injection, respectively. This
was resolved within 24 h, indicating that sickness
behavior was acute.

GFAP expression in the cortex differed significantly
between experimental groups (F3,32 = 57.92; P <
0.001) [Figure 3]. LPS preconditioning significantly
reduced GFAP levels after TBI according to oneway ANOVA and post-hoc Tukey’s test (q = 8.70,
P < 0.001). No difference was observed between
sham-injured and LPS-treated animals (q = 2.89, P
> 0.05), indicating that peripheral administration of
LPS did not activate astrocytes.

LPS preconditioning reduces M1 microglia
activation after TBI
To investigate the effect of LPS preconditioning on
classically activated microglia, CD68 expression
was quantified by stereology. Figure 4 shows a
significant difference in CD68 expression between
experimental groups (F3,32 = 28.22; P < 0.001).
The presence of M1 microglia (CD68 expression)
was significantly reduced after TBI following LPS
preconditioning compared with no LPS pretreatment
according to one-way ANOVA with post-hoc Tukey’s
test (q = 9.77, P < 0.001). Importantly, no significant
differences in CD68 expression were observed
between injured animals with LPS preconditioning
and sham-injured animals (q = 2.121, P > 0.05).
These findings were consistent with IBA-1 staining
for undifferentiated microglia, which showed a
qualitative reduction in LPS pre-conditioned animals
[Figure 5].

LPS
preconditioning
reduces
expression in astrocytes after TBI

OSMR

One of the primary mechanisms for regulating
astrocyte activation is neuropoietic cytokine signaling
through the gp130 receptor-signaling complex.[21] TBI
associated with significant vascular injury upregulates
members of the neuropoietic cytokine family, including

LPS preconditioning reduces neuronal
degeneration and glial activation following
TBI
Previous
studies
have
demonstrated
a
neuroprotective effect of LPS preconditioning
following controlled cortical impact injury with
large vascular insult.[2] Figure 2 shows a significant
difference in cortical FJB expression between
experimental groups (F3,32 = 59.79; P < 0.001). LPS
preconditioning significantly reduced FJB levels
following TBI according to one-way ANOVA with
Tukey’s post-hoc test (q = 8.50, P < 0.001). No
difference was observed between sham-injured and
LPS-treated animals (q = 0.13, P > 0.05), indicating
that peripheral administration of LPS did not induce
neurodegeneration.

Figure 1: Total locomotor activity after LPS injection by number of
beam breaks at 2, 4, 24, and 48 h after injection. Acute sickness
was present at 2 and 4 h but resolved by 24 h. ***P < 0.001. LPS:
lipopolysaccharide
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Figure 2: Neural degeneration increased following traumatic brain injury. Fluoro jade B significantly increased following traumatic brain
injury but LPS preconditioning ameliorated this effect. Scale bar = 50 µm. ***P < 0.001. LPS: lipopolysaccharide; TBI: traumatic brain
injuries; FJB: Fluoro-Jade B

Figure 3: Astrocyte reactivity increased following TBI. GFAP increased significantly following TBI but LPS preconditioning ameliorated the
effect. Scale bar = 50 µm. ***P < 0.001. LPS: lipopolysaccharide; TBI: traumatic brain injuries; GFAP: glial fibrillary acidic protein

OSMR.[22] We observed significant OSMR upregulation
following diffuse axonal injury [Figure 6]. OSMR
expression differed significantly between experimental
groups (F3,32 = 11.80; P < 0.05). OSMR expression
was reduced after TBI in LPS pre-conditioned animals
10

compared with no LPS pretreatment according to oneway ANOVA with post-hoc Tukey’s test (q = 6.51, P
< 0.05). No difference was observed between LPStreated animals and sham-injured rats at this time point
(q = 0.45, P > 0.05).
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GFAP expression was quantified to measure
astrocyte activation and was significantly different
between experimental groups (F3,32 = 6.30; P < 0.05)
[Figure 6]. LPS preconditioning significantly reduced
GFAP expression after TBI as shown by one-way
ANOVA and post-hoc Tukey’s test (q = 4.44; P <

LPS preconditioning neuroprotective

0.05). Again, no difference was observed between
LPS-treated and sham-injured rats at this time point
(q = 0.45; P > 0.05). Importantly, there was a strong
correlation between GFAP and OSMR expression
evidenced by the yellow overlay (overlap coefficient
r = 0.722), indicating a high degree of overlap within

Figure 4: M1 microglia activation increased significantly following TBI. CD68 was significantly increased following TBI but LPS
preconditioning ameliorated the effect. Scale bar = 50 µm. ***P < 0.001. LPS: lipopolysaccharide; TBI: traumatic brain injuries

Figure 5: No significant differences were observed in IBA-1 microglia staining between groups. LPS: lipopolysaccharide; TBI: traumatic
brain injuries
Neuroimmunology and Neuroinflammation ¦ Volume 4 ¦ January 20, 2017
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Figure 6: Colocalization of GFAP and OSMR with DAPI. GFAP (green) and OSMR (red) were significantly increased in the same cells
(merged yellow) following TBI. LPS preconditioning prevented OSMR upregulation. *P < 0.05. LPS: lipopolysaccharide; TBI: traumatic brain
injuries; GFAP: glial fibrillary acidic protein; OSMR: oncostatin M receptor

the same astrocyte. This was partially mitigated by
LPS preconditioning (overlap coefficient r = 0.478).

DISCUSSION
Diffuse axonal injury is induced consistently by the
weight drop method without producing a grossly
visible lesion.[23] We have previously confirmed that
the injury parameters used in this study induce
diffuse axonal injury by measuring β-amyloid
precursor protein expression.[24] The weight drop
model is ideal for testing neuroprotective strategies
because it induces consistent axonal damage and a
characteristic progression of traumatic axonal injury in
rodents.[25] Axonal injury reduces cerebral blood flow
following neurotrauma.[26] Therefore, it is potentially
worthwhile to investigate compounds that contribute
to vascular preconditioning. Vascular preconditioning
by heat activation reduces TBI severity and the extent
of axonal damage by selectively activating hypoxiainducible factor 1α.[27] Low-dose LPS pretreatment
has also been used for successful vascular
preconditioning in penetrating models of TBI.[28]
One proposed mechanism for LPS is a reduction of
inflammatory mediators before injury.[29] Inflammatory
mediators can activate gliosis.[30]
In this study, we show for the first time that lowdose LPS preconditioning is protective in a
12

closed-head model of diffuse axonal injury. LPS
preconditioning has previously been shown to be
protective in penetrating models, but there was
significant vascular disruption in these models and
they were generally more severe than our model
of diffuse axonal injury. The findings of the present
study are significant in that they demonstrate that
LPS preconditioning regulates microglia and OSMR
in a model of diffuse axonal injury. Furthermore,
these protective effects are sustained at one week
post-injury. Protection was established in a mild
injury model with no mortality or gross pathological
changes, indicating that LPS pretreatment may also
protect against mild neurotrauma.
Longhi et al.[2] showed that LPS preconditioning
alters IL-6 and OSM expression following TBI. In
this study, we demonstrated that LPS may exert a
neuroprotective effect against diffuse axonal injury
through modulation of neurodegeneration and the
gliosis response. This supports the notion that LPS
induces neuroprotective effects originally proposed
by Longhi et al.[2] We observed a transient acute
sickness induced by LPS pretreatment. However,
LPS preconditioning had the following effects,
including: reduced FJB, OSMR, GFAP, and CD68
expression. Decreased FJB staining was indicative
of reduced neurodegeneration. This has been
demonstrated in vitro by Zhu et al.,[31] and our
findings have now confirmed this in vivo. Increased
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FJB staining has been associated with motor deficits
following TBI.[32] In a future study, we plan to look at
the role of LPS preconditioning in preventing motor
deficits following TBI.
Reactive astrocytes can inhibit axonal regrowth
after an axon is severed.[33] OSM activity increases
in demyelinated areas, leading to an upregulation
of OSMR. This upregulation indicates a loss
of detrimental connectivity,[22] while decreased
OSMR indicates preservation of myelin integrity
and axonal tracts. Our findings show that LPS
preconditioning significantly reduces OSMR levels
[Figure 7]. Interestingly, GFAP expression was also
downregulated, which may reflect an interaction
between LPS and toll like receptor 4 (TLR4). Lowdose LPS administration can stimulate TLR4,
which activates signaling cascades to suppress
innate immunity and astrocyte activation. These
cell-signaling events permit axonal regeneration
without the threat of glial scar formation.[34] As long
as myelin integrity is maintained, neurons can
re-innervate most of their lost connections. The
clinical use of LPS preconditioning is obviously
limited because injury cannot be predicted, but
targeting TLR4 pharmacologically might represent
a reasonable strategy. Further work is needed to
determine the exact interactions between low-dose
LPS administration and TLR4.
In addition to effects on astrocytosis, LPS
preconditioning has also been associated with

LPS preconditioning neuroprotective

microglial changes. LPS can promote the infiltration
of macrophages into the brain, which helps resolve
the microglia response after diffuse traumatic
axonal injury.[35] Microglia is broadly grouped into
pro-inflammatory M1 microglia and pro-survival
anti-inflammatory M2 microglia.[36] The balance of
M1 to M2 microglia is tightly controlled following
injury.[37] M1 microglia can exacerbate axonal injury,
thereby limiting functional recovery. We showed
that LPS preconditioning selectively inhibited
the M1 response. LPS caused an acute increase
in pro-inflammatory markers, which may signal
peripheral macrophages to cross brain vasculature
by chemotaxis. Peripheral macrophages alter the
inflammatory mileu of the brain while attenuating
microglial activity.[38] In contrast, M2 microglia
are largely unaffected due to the earlier peak of
activation after injury, which we have shown using
non-differentiated IBA-1 imaging.[39] The brain
establishes functional recovery by shifting the
balance away from M1 microglia.
LPS has been associated with inflammation.
Suppressing inflammation limits the effect of LPS on
human physiology.[40] LPS increases tissue necrosis
factor α, interleukin 6, and interleukin 1 expression
[Figure 6].[41] LPS preconditioning reduces neuronal
loss and microglia activation in other injury models,
such as global hypoxia.[42] In the present study, LPS
preconditioning also significantly reduced neuronal
degeneration following diffuse axonal injury.
Chronic LPS-mediated inflammation is detrimental

Figure 7: Hypothetical schematic showing the mechanism of LPS action. LPS: lipopolysaccharide; TBI: traumatic brain injuries; OSMR:
oncostatin M receptor; TLR4: toll like receptor 4
Neuroimmunology and Neuroinflammation ¦ Volume 4 ¦ January 20, 2017
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to the brain, but acute LPS preconditioning provides
“inflamaprepping” that primes the nervous system
for response to injury.[43] Although inflamaprepping
is not a universal to all TBIs, it offers a potential
therapeutic advantage for a certain subset of
individuals, namely soldiers and athletes. Soldiers
and athletes are at increased risk of concussion and
subconcussive injury. Prevent injury and enhancing
recovery in these individuals is receiving increasing
attention. Inflamaprepping with a systemically
injected agent such as low-dose LPS is clinically
feasible and may limit gliosis and subsequent
glial scar formation by preparing the brain for
trauma. Ultimately this would facilitate rapid
axonal regeneration guided by preserved myelin
tracts. In the current study, we have shown that
inflamaprepping inhibits gliosis, downregulates the
OSMR receptor, and shifts the microglia phenotype
balance away from the pro-inflammatory M1
state, thereby decreasing neurodegeneration and
promoting neuroprotection. The benefits of this
neuroprotection on preventing behavioral decline
will be investigated in a future study.
There are some limitations to the present study.
Firstly, we did not assess post-injury behavior. Based
on our histopathologic findings, we expect that
LPS preconditioning prevents behavioral deficits
following TBI, but needs to be verified in a future
study. Secondly, we did not or examine glial marker
expression later than 7 days after LPS treatment.
This data would have indicated the current state of
gliosis and inflammation at the time of injury.
In conclusion, we have shown for the first time that
low-dose LPS preconditioning has protective effects
in a diffuse axonal injury model. LPS preconditioning
prevented both astrocyte and microglia activation
through downregulation of the OSMR receptor.
This protective effect was verified by reduced
FJB staining, indicating decreased degeneration.
Preconditioning and inflamaprepping may be viable
targets for TBI treatment and may prevent longterm behavioral sequelae in patients. Future work
will examine the long-term functional changes that
lead to neurodegenerative disease progression
and tauopathies. We will elucidate whether LPS
preconditioning reduces tau hyperphosphorylation
and improves behavior following repetitive
injury. Mediating the gliosis response with LPS
preconditioning may decrease neurodegeneration
and slow the development of tauopathy.
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